New triple therapy vs standard for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of nasopharyngeal cancer (called WHO type II or III).
- Your cancer should have spread to lymph nodes in the neck but not to other parts of the body (stage N3M0).
- You have not had any prior treatment for this cancer or any other cancer.
- You are between 18 and 65 years old and able to carry out daily activities with little or no help.
- Your blood counts and liver/kidney function must be within certain healthy ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination of three drugs (chidamide, toripalimab, and anlotinib) for people with nasopharyngeal cancer that has spread or come back. The goal is to see if this combination can help control the cancer when other treatments have not worked.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.